Singapore markets closed

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
16.47-0.96 (-5.49%)
As of 10:07AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close17.43
Open16.83
Bid17.10 x 800
Ask17.18 x 1100
Day's range15.86 - 17.41
52-week range3.21 - 18.33
Volume3,487,535
Avg. volume10,262,408
Market cap4.608B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript February 28, 2024 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]

  • Zacks

    Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

    Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GuruFocus.com

    Iovance Biotherapeutics Inc (IOVA) Reports Q4 and Full Year 2023 Financial Results

    Net Loss: Increased to $116.4 million in Q4 and $444.0 million for the full year, reflecting investment in commercial and development activities. Research and Development: R&D expenses rose to $87.5 million in Q4, driven by manufacturing and clinical trial costs. Selling, General and Administrative Expenses: Increased to $29.9 million in Q4, supporting business growth and Proleukin integration.